Filing Flows › Health Catalyst (HCAT) › Guidance & outlook
Health Catalyst (HCAT) guidance and outlook
Health Catalyst (HCAT) reaffirmed its guidance on Nov 5, 2026: Revenue $246M–$249M for FY2026; EBITDA $18.0M–$18.5M for FY2026. Health Catalyst's 10-Q filed Nov 5, 2026 makes 53 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $246M–$249M | reaffirmed |
| EBITDA | FY2026 | $18.0M–$18.5M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- The extent and duration of the impacts from these factors is uncertain, and we expect that continued impacts will continue to have a negative effect upon our clients, business and results of operations, and financial condition.
- On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (the OBBBA) into law, which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years and will create additional financial strain for many of our clients and prospective clients.
- We continue to anticipate that a higher proportion of our gross bookings will come from our existing client base as compared to historical levels.
- This expectation is driven by our belief that many existing clients that have already realized a strong financial return on investment (ROI), and are aligned on a long-term partnership framework, will be more receptive to expansion conversations, as compared to discussions with prospective clients.
- There has been no material change to this framework previously disclosed, and we do not plan to provide updates in the same format moving forward.
- Even among clients who have given notice on the infrastructure layer, we expect a number of clients will continue to use our application solutions going forward.
- As we referenced in the past, we expect to be generally through churn pressure associated with the DOS to Ignite migration by the end of 2027.
- We aim to continue to manage the business with a focus on operating efficiency, while balancing targeted investments to support disciplined growth and retention initiatives that we expect will benefit future results.
- In April 2026, we announced Project Nexus, a strategic initiative designed to fundamentally transform our operating model and advance each of these priorities.
- The Vitalware Transaction (as defined below), which is part of Project Nexus, provided us with the ability to fully repay all obligations under our Credit Agreement and terminate our Credit Agreement.
- We believe this extinguishment of our term loan debt provides us with increased flexibility to make targeted investments in our core business and move decisively on our priorities.
- Our priorities going forward will include strengthening and simplifying our commercial engine to drive technology ARR bookings, working to improve retention through clearer client value realization and technology innovation designed around how clients operate regardless of the infrastructure, and increasing efficiency and reducing time to value by eliminating operational complexity and scaling work through…
Health Catalyst's latest quarter
Health Catalyst, Q3 2026: revenue $56.3M (-26% year over year), operating margin 89.1%, net earnings $40.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Health Catalyst raise or lower its guidance?
Health Catalyst (HCAT) reaffirmed its guidance on Nov 5, 2026: Revenue $246M–$249M for FY2026; EBITDA $18.0M–$18.5M for FY2026.
What does Health Catalyst expect?
The extent and duration of the impacts from these factors is uncertain, and we expect that continued impacts will continue to have a negative effect upon our clients, business and results of operations, and financial condition. On July 4, 2025, President Trump signed the One Big Beautiful Bill Act (the OBBBA) into law, which is projected to reduce federal Medicaid spending by nearly $1 trillion over 10 years and will create additional financial strain for many of our clients and prospective clients. We continue to anticipate that a higher proportion of our gross bookings will come from our exi
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.